8-K/A: Perrigo Appoints Interim CEO, Details Compensation

Perrigo Company plc amends prior 8-K filing to detail the employment agreement for Albert Manzone as Interim President and Chief Executive Officer, including salary, bonus, and equity grants.

Summary

• Perrigo Company plc has filed an amendment to its Form 8-K to provide details on the employment agreement for Albert Manzone, who was appointed Interim President and Chief Executive Officer on June 7, 2026.
• The employment agreement is effective July 3, 2026, with a fixed term from June 7, 2026, to December 31, 2026.
• If a permanent CEO is not appointed by December 31, 2026, Mr. Manzone's employment may be extended month-to-month for up to 90 additional days.
• Mr. Manzone will receive an annual base salary of $1,270,000.
• He is eligible for a one-time cash bonus of $250,000 upon the expiry of the fixed term or termination due to a change of control.
• A special restricted stock unit equity grant with a fair value of $2,500,000 has been awarded, vesting upon the earlier of one year, the hiring of a permanent CEO, or a change of control.
• The filing also lists various debt instruments including senior notes and a senior loan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily providing procedural updates on executive compensation and terms rather than significant operational or financial performance news.

Positives

• Clear compensation structure established for the interim CEO, providing certainty during the transition period.
• Significant equity grant ($2,500,000) aligns the interim CEO's interests with long-term shareholder value.
• Defined fixed term for the interim CEO role provides a clear timeline for the search for a permanent CEO.

Negatives

• The need for an interim CEO and the ongoing search for a permanent replacement suggests potential leadership instability or a challenging executive search process.
• The fixed term ending December 31, 2026, with a potential for month-to-month extensions, indicates the search for a permanent CEO may extend beyond the initial period.

Risks

• The company is in the process of appointing a permanent CEO, which could lead to further leadership changes and strategic shifts.
• The employment agreement for the interim CEO has a defined end date, and if a permanent CEO is not found, it could lead to continued uncertainty in leadership.
• The company has various senior notes and a senior loan outstanding, which represent financial obligations and potential refinancing risks.

Future Outlook

The company is actively seeking a permanent President and CEO. The interim CEO's role is defined through December 31, 2026, with potential for extension, indicating an ongoing leadership transition.

Management Comments

• The filing details the compensatory arrangements for Mr. Manzone's service as Interim President and Chief Executive Officer.
• The employment agreement provides for a fixed term and potential extensions, along with specific salary, bonus, and equity components.

Industry Context

StockSavvy.ai notes that the appointment of an interim CEO and the detailed compensation package are common during periods of executive transition, especially in the pharmaceutical and consumer healthcare sectors where leadership stability is crucial for strategic execution and investor confidence.

Management Changes

Stakeholder Impact

• Shareholders: The clarity on interim CEO compensation and the ongoing search for a permanent leader provides transparency, though the extended search could be a point of concern.
• Employees: The leadership transition may create a period of uncertainty, but the defined role and compensation for the interim CEO offer some stability.
• Creditors: The company's existing debt obligations (senior notes, senior loan) remain in place, with no new information provided regarding their impact.

Next Steps

• The company will continue its search for a permanent President and Chief Executive Officer.
• Albert Manzone will serve as Interim President and Chief Executive Officer until a permanent replacement is appointed or the extended term concludes.

Key Dates

Keywords

Perrigo, 8-K/A, Interim CEO, Albert Manzone, Employment Agreement, Compensation, Restricted Stock Units, Leadership, Corporate Governance, Securities Filing